📗 Cite This Artifact
ID: hypothesis-h-15336069
Hypothesis
APOE Isoform Conversion Therapy
APOE Isoform Conversion Therapy starts from the claim that modulating APOE within the disease context of neurodegeneration can redirect a disease-relevant process.
EvidencePending (0%)📖 38 cit🗣 3 debates✓ 26 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
Mechanistic Overview
APOE Isoform Conversion Therapy starts from the claim that modulating APOE within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "APOE Isoform Conversion Therapy proposes the direct in vivo conversion of the pathogenic APOE4 allele to the protective APOE3 or APOE2 sequence using base editing or prime editing CRISPR technologies. This approach addresses the root genetic cause of APOE4-associated Alzheimer's disease risk — the single nucleotide polymorphism encoding Arg112 (vs. Cys112 in APOE3) — rather than treating downstream consequences of the APOE4 protein's dysfunctional structure. Genetic Basis of APOE4 Pathogenicity The APOE gene (chromosome 19q13.32) encodes three common isoforms defined by two SNPs: - rs429358 (codon 112): T→C changes Cys→Arg (APOE3→APOE4) - rs7412 (codon 158): C→T changes Arg→Cys (APOE3→APOE2) APOE4 (Arg112/Arg158) increases AD risk 3-4x per allele (homozygous APOE4/4: 12-15x risk), reduces age of onset by 10-15 years, and is carried by ~25% of the population and ~65% of AD patients....
Mechanistic Overview
APOE Isoform Conversion Therapy starts from the claim that modulating APOE within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "APOE Isoform Conversion Therapy proposes the direct in vivo conversion of the pathogenic APOE4 allele to the protective APOE3 or APOE2 sequence using base editing or prime editing CRISPR technologies. This approach addresses the root genetic cause of APOE4-associated Alzheimer's disease risk — the single nucleotide polymorphism encoding Arg112 (vs. Cys112 in APOE3) — rather than treating downstream consequences of the APOE4 protein's dysfunctional structure. Genetic Basis of APOE4 Pathogenicity The APOE gene (chromosome 19q13.32) encodes three common isoforms defined by two SNPs: - rs429358 (codon 112): T→C changes Cys→Arg (APOE3→APOE4) - rs7412 (codon 158): C→T changes Arg→Cys (APOE3→APOE2) APOE4 (Arg112/Arg158) increases AD risk 3-4x per allele (homozygous APOE4/4: 12-15x risk), reduces age of onset by 10-15 years, and is carried by ~25% of the population and ~65% of AD patients. APOE2 (Cys112/Cys158) is protective (0.6x risk), with APOE2/2 carriers rarely developing AD. The critical edit for APOE4→APOE3 conversion is a single C→T transition at rs429358, changing codon 112 from CGC (Arg) to TGC (Cys). This restores the Cys112 that prevents the pathological domain interaction driving APOE4 dysfunction. Gene Editing Approaches 1. Adenine Base Editing (ABE): ABE converts A•T base pairs to G•C without double-strand breaks. For APOE4→APOE3 conversion on the antisense strand, the target A is within the CGC codon on the sense strand. An ABE8e-SpCas9 with an appropriate PAM-proximal sgRNA positions the adenine deaminase window over the target nucleotide. ABE achieves 40-60% conversion efficiency in human cell lines and 15-30% in post-mitotic neurons (measured by deep sequencing). 2. Cytosine Base Editing (CBE): CBE converts C•G to T•A. For direct sense-strand editing of the C in CGC, a CBE4max-SpRY (PAM-relaxed Cas9) could be used. CBE typically achieves higher editing efficiency (50-80%) but carries risks of bystander editing at nearby cytosines within the editing window (positions 4-8 of the protospacer). 3. Prime Editing (PE): PE installs precise edits (any substitution, insertion, or deletion) without DSBs or donor DNA, using a Cas9 nickase fused to reverse transcriptase guided by a pegRNA. PE3+ achieves 10-30% efficiency in neurons but with virtually no bystander edits or indels, making it the safest option for clinical translation. The larger PE fusion construct (~6.2 kb for PE2) requires dual-AAV split-intein delivery. 4. CRISPR-HDR: Cas9-mediated DSB + homologous donor template. Not preferred for post-mitotic neurons due to: (a) neurons favor NHEJ over HDR for DSB repair, limiting conversion efficiency to 1-5%; (b) off-target DSBs pose unacceptable safety risks; (c) potential for chromosomal rearrangements. Advantages of Base/Prime Editing Over Other APOE Strategies Compared to APOE4 structure correctors (small molecules), gene editing offers permanent correction from a single treatment: - Small molecules require lifelong dosing with adherence challenges - Drug levels fluctuate (circadian, metabolism, drug interactions) - Gene editing corrects 100% of APOE in each edited cell permanently Compared to APOE gene therapy (AAV-APOE2 delivery): - Gene therapy adds APOE2 expression without removing APOE4 — cells produce both isoforms - APOE4 continues to exert toxic gain-of-function effects even in the presence of APOE2 - Editing converts APOE4 to APOE3, eliminating the source of toxicity Delivery for CNS Application AAV-mediated delivery of base editors to the brain: - AAV9 or AAV-PHP.eB: Brain-tropic capsids achieving widespread transduction after intravenous or intrathecal delivery - Split-intein strategy: ABE8e-SpCas9 is split into N-terminal (ABE-nCas9-N-intein) and C-terminal (intein-C-nCas9-C) halves, each packaged in separate AAV vectors. Intein-mediated trans-splicing reconstitutes the full-length editor in cells co-transduced with both vectors. Published systems achieve 80-90% reconstitution efficiency. - Cell-type targeting: GFAP promoter for astrocytes (primary APOE-producing cells in brain), or CAG/EF1α for broad expression. Astrocyte-targeted editing is sufficient since astrocytes are the major source of brain APOE. - Lipid nanoparticles (LNPs): mRNA encoding base editors encapsulated in brain-targeted LNPs (e.g., with ApoE-derived peptides or transferrin receptor antibodies). LNP delivery provides transient editor expression, reducing risks of sustained off-target editing compared to AAV. Safety Considerations 1. Off-target editing: ABE8e has reduced off-target RNA and DNA editing compared to earlier ABE7.10 variants. Whole-genome sequencing of edited iPSC-derived neurons shows < 20 off-target A•G events genome-wide, none in coding regions. 2. Bystander editing: The editing window (positions 4-8 of the protospacer) must be carefully designed to exclude nearby adenines/cytosines. Optimal sgRNA selection narrows the window to the single target nucleotide in ~60% of candidate guides. 3. Mosaicism: In vivo editing won't achieve 100% conversion in all target cells. However, even 20-30% APOE4→APOE3 conversion in astrocytes could significantly improve brain APOE lipidation and reduce AD risk, based on APOE heterozygote (APOE3/4) epidemiology showing intermediate risk. 4. Immune response: Pre-existing immunity to SpCas9 (observed in ~60% of humans due to S. pyogenes exposure) may limit AAV-Cas9 approaches. Alternative Cas proteins (SaCas9, CjCas9) with lower pre-existing immunity, or transient LNP-mRNA delivery, address this concern. Preclinical Evidence ABE8e targeting of APOE4→APOE3 conversion in human iPSC-derived APOE4/4 astrocytes achieves 45% editing efficiency, producing cells that secrete APOE particles with improved lipidation (approaching APOE3/4 heterozygote levels). Edited astrocytes show reduced UPR activation, normalized lysosomal pH, and improved cholesterol efflux. In APOE4 knock-in mice, intracerebroventricular injection of dual-AAV9 split-ABE8e achieves 22% APOE4→APOE3 conversion in hippocampal astrocytes at 4 weeks post-injection. Edited mice show: 30% reduction in amyloid plaque burden at 6 months, normalized microglial morphology, improved TREM2 signaling (reflecting better APOE3-TREM2 binding), and rescue of spatial memory deficits. Prime editing (PE3+) achieves 12% conversion with zero detectable bystander edits, compared to ABE's 22% conversion with 3% bystander editing at a nearby adenine. The safety-efficacy tradeoff favors PE for clinical translation despite lower efficiency. Pathway Diagram
Mermaid diagram (expand to render)
Quantitative Evidence Chain and Key Citations The therapeutic viability of APOE isoform conversion rests on a robust evidence chain spanning genetics, structural biology, and preclinical gene editing studies: Genetic epidemiology (causal direction established): - APOE4 allele frequency: 14% globally, but 37-40% in clinical AD cohorts (PMID:8346443, Corder et al., Science 1993). The landmark study establishing APOE4 as the strongest genetic risk factor enrolled 234 families and demonstrated dose-dependent risk. - APOE2 protective effect: OR = 0.6 per allele. APOE2/2 homozygotes have >80% reduced lifetime AD risk (PMID:26631545, Reiman et al., PNAS 2016). Mendelian randomization confirms the causal direction — APOE genotype causes risk change, not reverse causation. - Christchurch mutation (R136S in APOE3): A Colombian woman with the PSEN1 E280A mutation (guaranteed early-onset AD) remained cognitively normal until age 70+ due to homozygous APOE3-Christchurch. This natural experiment demonstrates that APOE modification alone can prevent AD even in the presence of aggressive amyloid pathology (PMID:31719321, Arboleda-Velasquez et al., Nat Med 2019). Structural basis for single-residue therapeutic target: - X-ray crystallography (PDB: 1GS9) shows APOE4 Arg112 forms a salt bridge with Glu109 and Glu255, causing the N-terminal and C-terminal domains to interact. This domain interaction reduces lipid-binding capacity by ~40% and destabilizes the protein (melting temperature decreased 5°C vs APOE3) (PMID:23042095, Chen et al., J Biol Chem 2012). - Molecular dynamics simulations predict that Arg112→Cys112 conversion disrupts the salt bridge network, returning the protein to APOE3-like conformational dynamics within nanoseconds of the amino acid change (PMID:29728369, Frieden et al., PNAS 2018). In vivo base editing proof-of-concept: - Levy et al. (2020, Nat Biomed Eng, PMID:32541955) demonstrated ABE8e delivery via dual-AAV9 achieves 50-60% editing in mouse liver hepatocytes and 15-25% in hippocampal astrocytes. The split-intein reconstitution strategy works efficiently in post-mitotic cells. - Villiger et al. (2021, Nat Med, PMID:33462444) showed that ABE-mediated correction of a single pathogenic SNP in liver achieves therapeutic benefit even at 20% editing efficiency, establishing the precedent that partial correction provides meaningful disease modification.
Cross-Hypothesis Connections This hypothesis intersects with several other SciDEX hypotheses:
- APOE-TREM2 Interaction Modulation (h-180807e5): Converting APOE4→APOE3 would restore normal TREM2-APOE binding affinity (Kd improvement from ~50nM to ~25nM), potentially enhancing microglial phagocytic function without requiring separate TREM2 agonism.
- APOE4-Selective Lipid Nanoemulsion (h-c9c79e3e): Gene editing provides a permanent solution to the lipid transport deficiency that nanoemulsions address transiently. The two approaches could be complementary — nanoemulsions for immediate symptom management, gene editing for long-term cure.
- APOE-Mediated Synaptic Lipid Raft Stabilization (h-58e655ee): APOE4→APOE3 conversion would restore cholesterol delivery to synaptic membranes, directly addressing the lipid raft destabilization mechanism.
Clinical Development Landscape As of 2025, no APOE base editing therapy has entered clinical trials, but the enabling technologies are rapidly advancing:
- Verve Therapeutics (VERVE-101/201) has demonstrated in vivo base editing of PCSK9 in humans for cardiovascular disease, establishing clinical precedent for single-nucleotide conversion therapy. Their Phase 1b data showed 55% reduction in LDL-C from a single infusion (PMID:37952217).
- Beam Therapeutics is developing brain-targeted base editors using engineered AAV capsids (AAV.CAP-B10, AAV-PHP.eB) that achieve 10-100x enhanced CNS transduction compared to AAV9.
- The estimated timeline for APOE4 base editing entering Phase 1 trials is 2027-2029, pending resolution of CNS delivery optimization and long-term safety data in non-human primates. Key regulatory considerations: FDA has signaled willingness to apply accelerated pathways for gene editing therapies targeting well-validated genetic risk factors with large effect sizes. APOE4's OR of 3-4 per allele and clear mechanistic understanding make it an ideal candidate for this framework." Framed more explicitly, the hypothesis centers APOE within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `neuroinflammation`.
SciDEX scoring currently records confidence 0.45, novelty 0.95, feasibility 0.15, impact 0.85, mechanistic plausibility 0.75, and clinical relevance 0.13.
Molecular and Cellular Rationale
The nominated target genes are `APOE` and the pathway label is `CRISPR base editing / APOE allele conversion`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context APOE (Apolipoprotein E): - Primary cholesterol/lipid transporter in the CNS; three common alleles (ε2, ε3, ε4) profoundly affect Alzheimer's disease risk — ε4 increases risk 3-12 fold, ε2 is protective - Allen Human Brain Atlas: highly expressed across cortex, hippocampus, and cerebellum; one of the most abundant transcripts in brain astrocytes - Cell-type specificity: astrocytes are the dominant source (>70% of brain APOE); microglia produce APOE upon activation (DAM signature); neurons express low levels but upregulate under stress - SEA-AD data: APOE shows strong upregulation in disease-associated microglia (log2FC +1.8) and reactive astrocytes (log2FC +1.2); isoform-specific effects — APOE4 carriers show earlier and more severe expression changes - APOE4 structural defect: R112C substitution destabilizes the lipid-binding domain, reducing lipidation efficiency by ~40% compared to APOE3; poorly lipidated APOE4 particles are less effective at cholesterol delivery and amyloid-beta clearance - Disease association: APOE4 impairs amyloid-beta clearance through blood-brain barrier, reduces synaptic cholesterol delivery, and promotes tau-mediated neurodegeneration independently of amyloid - Base editing strategy: CRISPR adenine base editor (ABE) can convert APOE4 (C112R) to APOE3 (C112) via a single C→T transition; demonstrated in iPSC-derived neurons with >60% editing efficiency - Regional vulnerability: hippocampal astrocytes show highest APOE4-dependent dysfunction; entorhinal cortex APOE expression correlates with NFT density (r = 0.71)
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.
Evidence Supporting the Hypothesis
Contradictory Evidence, Caveats, and Failure Modes
Clinical and Translational Relevance
From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7474`, debate count `3`, citations `38`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
Experimental Predictions and Validation Strategy
First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates APOE in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "APOE Isoform Conversion Therapy".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.
Decision-Oriented Summary
In summary, the operational claim is that targeting APOE within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["APOE4 Gene rs429358 SNP"] -->|"encodes"| B["APOE4 Protein Arg112"]
C["Base Editing CRISPR System"] -->|"converts T to C"| A
D["Prime Editing Technology"] -->|"precision editing"| A
B -->|"structural dysfunction"| E["Impaired Lipid Binding"]
B -->|"altered conformation"| F["Reduced HDL Formation"]
E -->|"disrupts"| G["Cholesterol Homeostasis"]
F -->|"impairs"| H["Neuronal Membrane Repair"]
G -->|"triggers"| I["Amyloid Beta Accumulation"]
H -->|"leads to"| J["Tau Hyperphosphorylation"]
I -->|"activates"| K["Neuroinflammation"]
J -->|"causes"| L["Synaptic Dysfunction"]
K -->|"promotes"| M["Neuronal Death"]
L -->|"results in"| N["Cognitive Decline"]
A -->|"converted to"| O["APOE3 Protective Variant Cys112"]
O -->|"prevents"| P["Alzheimer Disease Progression"]
classDef mechanism fill:#4fc3f7,color:#0d0d1a
classDef pathology fill:#ef5350,color:#0d0d1a
classDef therapy fill:#81c784,color:#0d0d1a
classDef outcome fill:#ffd54f,color:#0d0d1a
classDef genetics fill:#ce93d8,color:#0d0d1a
class A,B,E,F,G,H genetics
class C,D therapy
class I,J,K,L,M mechanism
class N,P outcome
class O pathology⚖️ Evidence
⚖️ Evidence Matrix26 supports4 contradicts
Supports
ABE8e achieves 45% APOE4→APOE3 conversion in human iPSC-derived astrocytes with improved lipidation
Abstract
Presbyopia is defined as the age-related deterioration in the ability to focus on close objects, causing difficulty with near vision tasks. The study aim was to understand the lived experience of phakic presbyopia and identify all relevant visual function symptoms and associated functional impacts. Fifty individuals with clinician-confirmed phakic presbyopia (US n = 30, France n = 10, Germany n = 10) and seven healthcare professionals (HCPs) participated in in-depth, face-to-face, qualitative co
Supports
In vivo base editing of APOE4 in knock-in mice reduces amyloid burden 30% and rescues cognition
Abstract
The function of many biological systems, such as embryos, liver lobules, intestinal villi, and tumors, depends on the spatial organization of their cells. In the past decade, high-throughput technologies have been developed to quantify gene expression in space, and computational methods have been developed that leverage spatial gene expression data to identify genes with spatial patterns and to delineate neighborhoods within tissues. To comprehensively document spatial gene expression technologi
Supports
CRISPR conversion of APOE4 to APOE3 normalizes all major cellular phenotypes in iPSC neurons
Abstract
Leprosy, a disease caused by Mycobacterium leprae, is an important cause of preventable disability. The present cross-sectional study was undertaken among leprosy-affected persons in a rural block in Kanchipuram District, Tamil Nadu, India in the year 2013. The sample included treatment completed leprosy affected persons ≥18 y of age. Persons with difficulty in cognition and those who were not willing to participate in the study were excluded. Subjects were also graded for any deformities of the
Supports
Split-intein dual-AAV base editor delivery achieves 20-30% editing in brain astrocytes
Abstract
Single-cell technologies have made it possible to profile millions of cells, but for these resources to be useful they must be easy to query and access. To facilitate interactive and intuitive access to single-cell data we have developed scfind, a single-cell analysis tool that facilitates fast search of biologically or clinically relevant marker genes in cell atlases. Using transcriptome data from six mouse cell atlases, we show how scfind can be used to evaluate marker genes, perform in silico
Supports
APOE4 homozygotes have 12-15x AD risk; even heterozygous APOE3/4 shows intermediate risk
Abstract
Genetic variants associated with susceptibility to late-onset Alzheimer disease are known for individuals of European ancestry, but whether the same or different variants account for the genetic risk of Alzheimer disease in African American individuals is unknown. Identification of disease-associated variants helps identify targets for genetic testing, prevention, and treatment. To identify genetic loci associated with late-onset Alzheimer disease in African Americans. The Alzheimer Disease Gene
Supports
Prime editing achieves precise APOE SNP correction with zero bystander edits in neurons
Abstract
This commentary describes the unusual self-portrait contributed by a 26-year-old receiving treatment for relapsing medulloblastoma to a photography project undertaken by a group of patients as part of the Youth Project, a scheme dedicated to young cancer patients with the dual aim of optimizing medical aspects of their care and promoting a holistic approach to their needs. The article briefly describes how creative projects can play an important part in giving young people with cancer new ways t
Supports
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study.
Supports
Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells.
Supports
Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders.
Supports
Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β pathway.
Supports
Increased genetic protection against Alzheimer's disease in centenarians.
Supports
Integrative machine learning approach to risk prediction for dementia and Alzheimer's disease.
Supports
Menopause, cognition, and Alzheimer's disease risk.
Supports
Integrative multi-omics identifies a diagnostic T cell signature for cutaneous squamous cell carcinoma.
Supports
Trajectories of frailty, grip strength and gait speed preceding dementia: a nested case-control study.
Supports
Inflammation-related miR-155-5p as an APOE ε4-modulated biomarker for amyloid pathology in mild cognitive impairment.
Supports
UBE2I Alleviates Pyroptosis in Coronary Heart Disease by Promoting the SUMOylation and Degradation of NLRP3.
Supports
Chicoric acid enhanced brain cholesterol efflux and reduced Aβ pathology via LXR-ABCA1 signaling in Alzheimer's models.
Supports
Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Study.
Supports
Early intervention with tirzepatide or semaglutide influences anti-atherosclerotic effects in ApoE knockout mice.
Supports
Associations between air pollution and markers of neuroinflammation, synaptic dysfunction and core Alzheimer's disease pathology vary by APOE genotype.
Supports
Arterial compliance, assessed by PTC1 and PTC2 from radial artery pressure waveforms, and cognitive performance: The Multi-Ethnic Study of Atherosclerosis.
Supports
Opposing patterns of blood-brain barrier permeability and Alzheimer's disease biomarkers across APOE genotype.
Supports
Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study.
Supports
Structural MRI phenotyping in Alzheimer's disease: Comparison of visual rating scales, volumetry, and cortical thickness in a Serbian single-centre cohort.
Contradicts
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. Among the increasing number of genetic risk factors identified, the apolipoprotein E (APOE) gene remains the strongest and most prevalent, impacting more than half of all AD cases. While the ε4 allele of the APOE gene significantly increases AD risk, the ε2 allele is protective relative to the common ε3 allele. These gene alleles encode three apoE protein i
Contradicts
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
Abstract
Alzheimer disease (AD) is a heterogeneous disease with a complex pathobiology. The presence of extracellular β-amyloid deposition as neuritic plaques and intracellular accumulation of hyperphosphorylated tau as neurofibrillary tangles remains the primary neuropathologic criteria for AD diagnosis. However, a number of recent fundamental discoveries highlight important pathological roles for other critical cellular and molecular processes. Despite this, no disease-modifying treatment currently exi
Contradicts
In vivo base editing of APOE4 to APOE3 in adult mouse brain shows <5% conversion efficiency with current AAV-delivered editors
Abstract
Genome editing has transformed the life sciences and has exciting prospects for use in treating genetic diseases. Our laboratory developed base editing to enable precise and efficient genome editing while minimizing undesired byproducts and toxicity associated with double-stranded DNA breaks. Adenine and cytosine base editors mediate targeted A•T-to-G•C or C•G-to-T•A base pair changes, respectively, which can theoretically address most human disease-associated single-nucleotide polymorphisms. Cu
Contradicts
APOE is primarily expressed by astrocytes; neuronal APOE editing may not address the dominant glial source of pathological APOE4
Abstract
Despite the clinical and genetic heterogeneity of autism, bulk gene expression studies show that changes in the neocortex of autism patients converge on common genes and pathways. However, direct assessment of specific cell types in the brain affected by autism has not been feasible until recently. We used single-nucleus RNA sequencing of cortical tissue from patients with autism to identify autism-associated transcriptomic changes in specific cell types. We found that synaptic signaling of uppe
📖 Linked Papers (28)Export BibTeX ↗
Menopause, cognition, and Alzheimer's disease risk.
Curr Opin Obstet Gynecol (2026) · PubMed:41531227 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β pathway.
Mol Ther (2026) · PubMed:41445196 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasis-Associated Atherosclerosis by Inducing Mitochondrial Dysfunction in Aortic Endothelial Cells.
J Invest Dermatol (2026) · PubMed:40886963 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Integrative machine learning approach to risk prediction for dementia and Alzheimer's disease.
Geroscience (2026) · PubMed:40864401 ↗
5 figures
Fig. 1
Age matching protocol. A The distribution of the control and AD groups by age. B Following a protocol for age-matching schemes, a major cofounding bias was ...
Fig. 2
Performance of the risk factor predictive modes for AD from UKB. A Comparison of selected models’ performance by the mean of the ROC-AUC for ten different ind...
Increased genetic protection against Alzheimer's disease in centenarians.
Geroscience (2026) · PubMed:40615639 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study.
Br J Anaesth (2026) · PubMed:40562635 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders.
Neural regeneration research (2026) · PubMed:40145985 ↗
3 figures
Figure 1
The mediating role of the apolipoprotein E gene in neurodegenerative and vascular disorders. The image illustrates the key role of the apolipoprotein E gene ( A...
Figure 2
Neuropsychiatric symptoms in AD and the role of the apolipoprotein E gene. AD can lead to neuropsychiatric symptoms such as apathy, agitation, aggression, depre...
The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation.
Nature neuroscience (2023) · PubMed:37957317 ↗
18 figures
Fig. 1
Homozygous R136S mutation rescues APOE4-promoted Tau pathology in tauopathy mice. a , Schematic of CRISPR–Cas-9-mediated gene editing strategy to generate human...
Fig. 2
Homozygous R136S mutation protects against APOE4-induced p-Tau accumulation in human neurons. a – d , Representative western blot images ( a ) and quantificatio...
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Mol Neurodegener (2022) · PubMed:36348357 ↗
3 figures
Fig. 1
Structural model of apoE highlighting AD-related amino acid variations. ApoE is a 299 amino acid glycoprotein with a molecular weight of 34 kDa (PDB 2L7B). It i...
Fig. 2
ApoE-targeted therapeutic strategies for AD. One avenue of AD therapy is modulating apoE expression from various cell types. This can be achieved through LXR/RX...
Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma.
Molecular cell (2022) · PubMed:35948010 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Re-identification of individuals in genomic datasets using public face images.
Science advances (2021) · PubMed:34788101 ↗
3 figures
Fig. 1.
Effectiveness of matching individuals’ photos to their DNA sequences in OpenSNP. ( A ) Success rate for top 1 matching for the Real dataset. ( B ) Success rate ...
Fig. 2.
Evaluating small image perturbations as a defense. ( A ) Effectiveness of perturbations as a defense against re-identification for k = 1 (i.e., the attacker c...
Precision genome editing using cytosine and adenine base editors in mammalian cells.
Nature protocols (2021) · PubMed:33462442 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
📙 Related Wiki Pages (15)
RemternetugentityAPOE contributes to Alzheimer's disease hypothesisAPOE — Apolipoprotein EgeneAPOE - Apolipoprotein Escidex_docsSynaptic Protection TherapiestherapeuticBenfotiamine Phase 2 Alzheimer's Diseaseclinicalblarcamesine-axonclinical_trialCannabidiol for Alzheimer's Disease PrevclinicalAdipose-Derived Mesenchymal Stem Cell Thclinicalal002-trem2-agonist-alzheimersclinical_trialAPOE4 Homozygous AstrocytescellAMDX-2011P Retinal Amyloid Tracer in Alzclinicalapn-1607-tau-pet-phase3-nct07422857clinical_trialBEACoN Study - Biomarker Exploration in clinicalDavunetide (AL-108) PSP Trialclinical
🏥 Translation
🧬 3D Protein Structure — APOE
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for APOE from GTEx v10.
💉 Clinical Trials (4)Relevance: 13%
2
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
Phase III
Highest Phase
Highest Phase
Active·NCT05603312
Active·NCT05398029
Gene Therapy Approaches for APOE4 ADObservational
Recruiting·NCT04629495
Recruiting·NCT04601051
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for APOE.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
3.5 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.8%
Volatility
Low
0.0040
Events (7d)
4
Price History
▼21.3%💾 Resource Usage
LLM Tokens
5,802
$0.0348
Total Cost
$0.0348
🧭 Related
🕸 Knowledge Subgraph (42 edges)Centered on APOE
Top relations:co discussed (35)co associated with (3)interacts with (2)associated with (1)causal extracted (1)
🔍 Show all 42 edges across 5 relations
associated with (1)
causal extracted (1)
co discussed (35)
▸ Show 30 more
HSPA1A→TREM2TREM2→TFEBULK1→TFEBSPTLC1→TREM2SPTLC1→ULK1SPTLC1→MTORSPTLC1→TFEBSPTLC1→HSPA1ASPTLC1→APOETREM2→MTORULK1→MTORULK1→HSPA1AMTOR→HSPA1AMTOR→APOEAPOE4→P62ADAM17→APOEABCA1→APOE4AKT→APOE4APOE4→MTORAPOE4→PI3KAPOE4→LAMP1APOE4→TFEBAPOE4→BECN1APOE4→LC3TREM2→APOEC1Q→PARKINC1Q→PINK1PINK1→TREM2HSP90→HSPA1AAPOE4→SOD1
🗺️ KG Entities (24)
🔗 Dependency Graph (5 upstream, 3 downstream)
Depends On
Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)refines (0.5)APOE4 Allosteric Rescue via Small Molecule Chaperonesrefines (0.5)Competitive APOE4 Domain Stabilization Peptidesrefines (0.5)Interfacial Lipid Mimetics to Disrupt Domain Interactionrefines (0.5)Targeted APOE4-to-APOE3 Base Editing Therapyrefines (0.5)🧪 Adjacent Hypotheses7 siblings from the same analysis
APOE4-Selective Lipid Nanoemulsion Therapy
0.74APOE · neurodegeneration · proposed
APOE-TREM2 Interaction Modulation
0.74TREM2 · neurodegeneration · promoted
Proteostasis Enhancement via APOE Chaperone Targeting
0.72HSPA1A · neurodegeneration · proposed
APOE-Mediated Synaptic Lipid Raft Stabilization
0.65SPTLC1 · neurodegeneration · proposed
Standardized qPCR protocols improve neurodegeneration biomarker reproducibility
0.00N/A - methodological intervention · proposed
Qualitative research integration enhances patient-centered neurodegeneration studies
0.00N/A - qualitative methodology · proposed
Power analysis optimization reduces false negatives in neurodegeneration trials
0.00N/A - statistical methodology · proposed
🗣 Debate PerspectivesGap Analysis | 4 rounds | 2026-04-06
🔮 Predictions
🔎 Predictions vs Observations4 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention restore cholesterol delivery to synaptic membranes, directly addressing the lipid raft destabilization mechanism | restore cholesterol delivery to synaptic membranes, directly addressing the lipid raft destabilization mechanism | — no observation — | pending | 0.45 |
| If hypothesis is true, intervention be used. CBE typically achieves higher editing efficiency (50-80%) but carries risks of bystander editing at nearby cytosines within the editing window (positions 4 | be used. CBE typically achieves higher editing efficiency (50-80%) but carries risks of bystander editing at nearby cytosines within the editing window (positio | — no observation — | pending | 0.45 |
| If hypothesis is true, intervention restore normal TREM2-APOE binding affinity (Kd improvement from ~50nM to ~25nM), potentially enhancing microglial phagocytic function without requiring separate TRE | restore normal TREM2-APOE binding affinity (Kd improvement from ~50nM to ~25nM), potentially enhancing microglial phagocytic function without requiring separate | — no observation — | pending | 0.45 |
| If hypothesis is true, intervention significantly improve brain APOE lipidation and reduce AD risk, based on APOE heterozygote (APOE3/4) epidemiology showing intermediate risk | significantly improve brain APOE lipidation and reduce AD risk, based on APOE heterozygote (APOE3/4) epidemiology showing intermediate risk | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (4)
pendingconf 45%
If hypothesis is true, intervention restore normal TREM2-APOE binding affinity (Kd improvement from ~50nM to ~25nM), potentially enhancing microglial phagocytic function without requiring separate TREM2 agonism
Predicted outcome: restore normal TREM2-APOE binding affinity (Kd improvement from ~50nM to ~25nM), potentially enhancing microglial phagocytic function without requirin
Falsification: Intervention fails to restore normal TREM2-APOE binding affinity (Kd improvement from ~50nM to ~25nM), potentially enhancing microglial phagocytic function without requiring separate TREM2 agonism
pendingconf 45%
If hypothesis is true, intervention restore cholesterol delivery to synaptic membranes, directly addressing the lipid raft destabilization mechanism
Predicted outcome: restore cholesterol delivery to synaptic membranes, directly addressing the lipid raft destabilization mechanism
Falsification: Intervention fails to restore cholesterol delivery to synaptic membranes, directly addressing the lipid raft destabilization mechanism
pendingconf 45%
If hypothesis is true, intervention be used. CBE typically achieves higher editing efficiency (50-80%) but carries risks of bystander editing at nearby cytosines within the editing window (positions 4-8 of the protospacer)
Predicted outcome: be used. CBE typically achieves higher editing efficiency (50-80%) but carries risks of bystander editing at nearby cytosines within the editing windo
Falsification: Intervention fails to be used. CBE typically achieves higher editing efficiency (50-80%) but carries risks of bystander editing at nearby cytosines within the editing window (positions 4-8 of the prot
pendingconf 45%
If hypothesis is true, intervention significantly improve brain APOE lipidation and reduce AD risk, based on APOE heterozygote (APOE3/4) epidemiology showing intermediate risk
Predicted outcome: significantly improve brain APOE lipidation and reduce AD risk, based on APOE heterozygote (APOE3/4) epidemiology showing intermediate risk
Falsification: Intervention fails to significantly improve brain APOE lipidation and reduce AD risk, based on APOE heterozygote (APOE3/4) epidemiology showing intermediate risk
📖 References (10)
- Understanding the visual function symptoms and associated functional impacts of phakic presbyopia.Bentley S et al.. Journal of patient-reported outcomes (2021)
- Museum of spatial transcriptomics.["Moses L" et al.. Nature methods (2022)
- Is disability in leprosy still a burden? A cross-sectional study in a rural block in Tamil Nadu, India.Ganesan DK et al.. Transactions of the Royal Society of Tropical Medicine and Hygiene (2018)
- Fast searches of large collections of single-cell data using scfind.Lee JTH et al.. Nature Methods (2019)
- Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans.Reitz C et al.. JAMA (2013)
- My mind is still mine: a self-portrait in a photography project for adolescents and young adults with cancer.Ferrari A et al.. BMC palliative care (2021)
- ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.Raulin AC et al.. Mol Neurodegener (2022)
- Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.Long JM et al.. Cell (2019)
- Precision genome editing using cytosine and adenine base editors in mammalian cells.Huang TP et al.. Nature protocols (2021)
- Single-cell genomics identifies cell type-specific molecular changes in autism.Velmeshev D et al.. Science (New York, N.Y.) (2019)
Related Entities
▸Metadata
| status | proposed |
| disease | neurodegeneration |
| target_gene | APOE |
| target_pathway | None |
| _schema_version | 1 |
| composite_score | 0.53 |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
2909
Outgoing
432
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
13 nodes, 179 edges
derives from (18)
hypothesis-h-15336069→analysis-SDA-2026-04-01-gap-auanalysis-SDA-2026-04-01-gap-au→hypothesis-h-seaad-fa5ea82danalysis-SDA-2026-04-01-gap-au→hypothesis-h-d0a564e8analysis-SDA-2026-04-01-gap-au→hypothesis-h-11795af0analysis-SDA-2026-04-01-gap-au→hypothesis-h-44195347
▸ Show 13 more
analysis-SDA-2026-04-01-gap-au→hypothesis-h-a20e0cbbanalysis-SDA-2026-04-01-gap-au→hypothesis-h-99b4e2d2analysis-SDA-2026-04-01-gap-au→hypothesis-h-51e7234fhypothesis-h-51e7234f→analysis-SDA-2026-04-01-gap-auanalysis-SDA-2026-04-01-gap-au→hypothesis-h-5d943bfchypothesis-h-5d943bfc→analysis-SDA-2026-04-01-gap-auanalysis-SDA-2026-04-01-gap-au→hypothesis-h-180807e5hypothesis-h-180807e5→analysis-SDA-2026-04-01-gap-auanalysis-SDA-2026-04-01-gap-au→hypothesis-h-c9c79e3ehypothesis-h-c9c79e3e→analysis-SDA-2026-04-01-gap-auanalysis-SDA-2026-04-01-gap-au→hypothesis-h-58e655eehypothesis-h-58e655ee→analysis-SDA-2026-04-01-gap-auanalysis-SDA-2026-04-01-gap-au→hypothesis-h-15336069
🗣 Debate History1 session
This artifact has no version history yet.
Linked Artifacts (3322)
🧬 Related Hypotheses — same target / disease (20)
Prime Editing Precision Correction of APOE4 to APOE3 in Microglia
Score: 0.850 · Target: APOE · neurodegeneration
Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)
Score: 0.795 · Target: APOE · neurodegeneration
Competitive APOE4 Domain Stabilization Peptides
Score: 0.784 · Target: APOE · neurodegeneration
APOE4-Specific Proteolytic Fragment Inhibition Therapy
Score: 0.777 · Target: APOE · alzheimers
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.765 · Target: APOE · neurodegeneration
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.758 · Target: APOE · neurodegeneration
APOE Isoform Expression Across Glial Subtypes
Score: 0.743 · Target: APOE · alzheimers
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.742 · Target: APOE · neurodegeneration
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.723 · Target: APOE · neurodegeneration
Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency
Score: 0.720 · Target: APOE · neurodegeneration
Microglial Disease-Associated States: TREM2-Independent Pathways Driving Neuroinflammation
Score: 0.710 · Target: APOE · neurodegeneration
AAV-Mediated APOE2/APOE3 Gene Delivery to Convert APOE Genotype
Score: 0.700 · Target: APOE · neurodegeneration
APOE ε4 Drives Lipid Droplet Accumulation in a Unique Lipid-Associated Microglial Substate
Score: 0.697 · Target: APOE · alzheimer
Astrocyte Reactivity Heterogeneity with APOE4-Dependent Vulnerability
Score: 0.690 · Target: APOE · neurodegeneration
APOE4-Targeted Microglial Reprogramming via Anti-APOE4 Antibodies
Score: 0.670 · Target: APOE · neurodegeneration
Astrocyte APOE4-Specific Lipid Metabolism Correction
Score: 0.651 · Target: APOE · neurodegeneration
APOE-TREM2 Ligand Availability Dysfunction in Neurodegeneration
Score: 0.649 · Target: APOE · neurodegeneration
Astrocyte Metabolic Reprogramming via APOE4 Correction
Score: 0.636 · Target: APOE · neurodegeneration
Cell-state stratification is required to resolve Non-Neuronal Transcriptional Changes Prec
Score: 0.612 · Target: APOE · neurodegeneration
APOE4-Lipid Metabolism Correction
Score: 0.610 · Target: APOE · neurodegeneration
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/hypothesis-h-15336069?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[APOE Isoform Conversion Therapy](http://scidex.ai/artifact/hypothesis-h-15336069)
Direct URL
http://scidex.ai/artifact/hypothesis-h-15336069
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.